Lesson plan
Cip2a
Protein CIP2A also known as cancerous inhibitor of PP2A (CIP2A) is a protein that in humans is encoded by the KIAA1524 gene. CIP2A is a regulatory protein involved in the inhibition of the serine-threonine phosphatase activity of Protein phosphatase 2A (PP2A). PP2A is a trimeric enzyme composed of a catalytic C-subunit, a scaffolding A-subunit, and various regulatory B-subunits, which collectively dephosphorylate a vast majority of cellular serine/threonine phosphorylated proteins, including many involved in cancer progression. CIP2A has been shown to regulate phosphorylation and activity of numerous oncoproteins, promoting malignant cell growth and tumorigenesis in various human cancers. High expression levels of CIP2A have been observed in multiple cancer types, such as head and neck cancer, colon cancer, gastric cancer, breast cancer, prostate cancer, and lung cancer, correlating with poor patient prognosis and disease aggressivity. Additionally, CIP2A is implicated in resistance to cancer treatments, such as imatinib in chronic myeloid leukemia.
Article summary
Protein CIP2A also known as cancerous inhibitor of PP2A (CIP2A) is a protein that in humans is encoded by the KIAA1524 gene. CIP2A is a regulatory protein involved in the inhibition of the serine-threonine phosphatase activity of Protein phosphatase 2A (PP2A). PP2A is a trimeric enzyme composed of a catalytic C-subunit, a scaffolding A-subunit, and various regulatory B-subunits, which collectively dephosphorylate a vast majority of cellular serine/threonine phosphorylated proteins, including many involved in cancer progression. CIP2A has been shown to regulate phosphorylation and activity of numerous oncoproteins, promoting malignant cell growth and tumorigenesis in various human cancers. High expression levels of CIP2A have been observed in multiple cancer types, such as head and neck cancer, colon cancer, gastric cancer, breast cancer, prostate cancer, and lung cancer, correlating with poor patient prognosis and disease aggressivity. Additionally, CIP2A is implicated in resistance to cancer treatments, such as imatinib in chronic myeloid leukemia.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.